Polymyositis and dermatomyositis epidemiology and demographics: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
| Line 35: | Line 35: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 23:47, 29 July 2020
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis epidemiology and demographics |
|
FDA on Polymyositis and dermatomyositis epidemiology and demographics |
|
CDC on Polymyositis and dermatomyositis epidemiology and demographics |
|
Polymyositis and dermatomyositis epidemiology and demographics in the news |
|
Blogs on Polymyositis and dermatomyositis epidemiology and demographics |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. Polymyositis commonly affects adults after second decades of their lives and it is rare among children. There is no racial predilection to polymyositis and dermatomyositis. The female to male ratio is approximately 2 to 1. Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.
Epidemiology and Demographics
Incidence
- The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.[1][2]
- In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.[3]
- In 1970, the age‐adjusted annual incidence of polymyositis was 5 cases per 100,000 individuals in USA hospital‐based retrospective study.[4]
Prevalence
- The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.[5]
- In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.[6]
- In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.[3]
Case-fatality rate/Mortality rate
- The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%.[3]
- The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.[3]
Age
- Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old.[7][2]
- Polymyositis commonly affects adults after second decades of their lives and it is rare among children.[7][8]
Race
- There is no racial predilection to polymyositis and dermatomyositis.
Gender
- Females are more commonly affected by polymyositis and dermatomyositis than males. The female to male ratio is approximately 2 to 1.[7]
Region
- Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.[9]
References
- ↑ Jacobson DL, Gange SJ, Rose NR, Graham NM (September 1997). "Epidemiology and estimated population burden of selected autoimmune diseases in the United States". Clin. Immunol. Immunopathol. 84 (3): 223–43. PMID 9281381.
- ↑ 2.0 2.1 Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
- ↑ 3.0 3.1 3.2 3.3 Airio, A.; Kautiainen, H.; Hakala, M. (2006). "Prognosis and mortality of polymyositis and dermatomyositis patients". Clinical Rheumatology. 25 (2): 234–239. doi:10.1007/s10067-005-1164-z. ISSN 0770-3198.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Schiffenbauer, Adam; Faghihi-Kashani, Sara; O’Hanlon, Terrence P.; Flegel, Willy A.; Adams, Sharon D.; Targoff, Ira N.; Oddis, Chester V.; Ytterberg, Steven R.; Aggarwal, Rohit; Christopher-Stine, Lisa; Shamim, Ejaz A.; Dellaripa, Paul F.; Danoff, Sonye K.; Mammen, Andrew; Miller, Frederick W. (2018). "The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis". Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.02.003. ISSN 0049-0172.
- ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.
- ↑ 7.0 7.1 7.2 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.